New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor

X. Feng, R. H. Pak, L. A. Kroger, J. K. Moran, D. G. DeNardo, C. F. Meares, Gerald L Denardo, S. J. DeNardo

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Monoclonal antibodies were raised against yttrium(III)-1, 4, 7, 10- tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (Y-DOTA) and copper(II)- 1, 4, 8, 11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (Cu- TETA). Four hybridomas with high Y-DOTA binding activity and one hybridoma with Cu-TETA activity were selected. MAbs were purified from mouse ascites by Protein A affinity chromatography and characterized. Affinity constants were determined by equilibrium dialysis and the highest affinity Y-DOTA MAb (K(aff) = 1.9 x 108 M-1) was further characterized by competitive ELISA. Gd-DOTA competed as well as Y-DOTA, whereas In-DOTA required 740x higher concentrations for 50% inhibition of this Y-DOTA MAb binding to human serum albumin-Y-DOTA-coated microtiter plates. These anti-metal chelate MAbs have potential use as vehicles for the pretargeted delivery of radiometal chelates to tumors.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalHybridoma
Volume17
Issue number2
StatePublished - 1998

ASJC Scopus subject areas

  • Immunology
  • Genetics

Fingerprint Dive into the research topics of 'New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor'. Together they form a unique fingerprint.

  • Cite this

    Feng, X., Pak, R. H., Kroger, L. A., Moran, J. K., DeNardo, D. G., Meares, C. F., Denardo, G. L., & DeNardo, S. J. (1998). New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. Hybridoma, 17(2), 125-132.